Cargando…

Synergistic effect of BCL2 and FLT3 co-inhibition in acute myeloid leukemia

Acute myeloid leukemia (AML) is a heterogeneous and complex disease, and treatments for this disease have not been curative for the majority of patients. In younger patients, internal tandem duplication of FLT3 (FLT3-ITD) is a common mutation for which two inhibitors (midostaurin and gilteritinib) w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Brinton, Lindsey T., Zhang, Pu, Williams, Katie, Canfield, Daniel, Orwick, Shelley, Sher, Steven, Wasmuth, Ronni, Beaver, Larry, Cempre, Casey, Skinner, Jordan, Cannon, Matthew, Govande, Mukul, Harrington, Bonnie, Lehman, Amy, Byrd, John C., Lapalombella, Rosa, Blachly, James S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Rapid Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7574303/ https://www.ncbi.nlm.nih.gov/pubmed/33076970 http://dx.doi.org/10.1186/s13045-020-00973-4

Ejemplares similares

Cotargeting of XPO1 Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Acute Myeloid Leukemia
por: Brinton, Lindsey T., et al.
Publicado: (2020)

Targeting OXPHOS de novo purine synthesis as the nexus of FLT3 inhibitor–mediated synergistic antileukemic actions
por: Zhang, Pu, et al.
Publicado: (2022)

Anti-tumor NAMPT inhibitor, KPT-9274, mediates gender-dependent murine anemia and nephrotoxicity by regulating SIRT3-mediated SOD deacetylation
por: Mitchell, Shaneice, et al.
Publicado: (2021)

Rare t(X;14)(q28;q32) translocation reveals link between MTCP1 and chronic lymphocytic leukemia
por: Walker, Janek S., et al.
Publicado: (2021)

Preclinical efficacy for a novel tyrosine kinase inhibitor, ArQule 531 against acute myeloid leukemia
por: Elgamal, Ola A., et al.
Publicado: (2020)

BMX kinase mediates gilteritinib resistance in FLT3-mutated AML through microenvironmental factors
por: Buelow, Daelynn R., et al.
Publicado: (2022)

Genomic analysis of cellular hierarchy in acute myeloid leukemia using ultrasensitive LC-FACSeq
por: Saygin, Caner, et al.
Publicado: (2021)

Correction: Genomic analysis of cellular hierarchy in acute myeloid leukemia using ultrasensitive LC-FACSeq
por: Saygin, Caner, et al.
Publicado: (2021)

Characterization and mitigation of fragmentation enzyme-induced dual stranded artifacts
por: Gregory, Thomas, et al.
Publicado: (2020)

Generation and characterization of a highly effective protein substrate for analysis of FLT3 activity
por: Chen, Yun, et al.
Publicado: (2012)

Dysregulation of PRMT5 in chronic lymphocytic leukemia promotes progression with high risk of Richter’s transformation
por: Hing, Zachary A., et al.
Publicado: (2023)

VIP152 is a selective CDK9 inhibitor with pre-clinical in vitro and in vivo efficacy in chronic lymphocytic leukemia
por: Sher, Steven, et al.
Publicado: (2022)

Uncovering the Genomic Landscape in Newly Diagnosed and Relapsed Pediatric Cytogenetically Normal FLT 3‐ITD AML
por: Buelow, Daelynn R., et al.
Publicado: (2019)

Targeting MYC activity in double-hit lymphoma with MYC and BCL2 and/or BCL6 rearrangements with epigenetic bromodomain inhibitors
por: Li, Weiping, et al.
Publicado: (2019)

Recurrent XPO1 mutations alter pathogenesis of chronic lymphocytic leukemia
por: Walker, Janek S., et al.
Publicado: (2021)

Simultaneous targeting of XPO1 and BCL2 as an effective treatment strategy for double-hit lymphoma
por: Liu, Yuanhui, et al.
Publicado: (2019)

MiR-424 and miR-155 deregulated expression in cytogenetically normal acute myeloid leukaemia: correlation with NPM1 and FLT3 mutation status
por: Faraoni, Isabella, et al.
Publicado: (2012)

Preclinical evaluation of the Hsp90 inhibitor SNX-5422 in ibrutinib resistant CLL
por: Chen, Timothy L., et al.
Publicado: (2021)

Large-Scale Drug Screen Identifies FDA-Approved Drugs for Repurposing in Sickle-Cell Disease
por: Cannon, Matthew, et al.
Publicado: (2020)

TP-0903 is active in models of drug-resistant acute myeloid leukemia
por: Jeon, Jae Yoon, et al.
Publicado: (2020)

Increased Frequencies of Gene and Chromosome Mutations after X‐Irradiation in Mouse Embryonal Carcinoma Cells Transfected with the bcl‐2 Gene
por: Taga, Masataka, et al.
Publicado: (2000)

Development of novel 5-FU modified siRNA against BCL-2 with enhanced efficacy and vehicle-free cellular uptake
por: Fesler, Andrew, et al.
Publicado: (2022)

Gilteritinib Inhibits Glutamine Uptake and Utilization in FLT3-ITD–Positive AML
por: Zavorka Thomas, Megan E., et al.
Publicado: (2021)

US-Approved Intra-Articular Hyaluronic Acid Injections are Safe and Effective in Patients with Knee Osteoarthritis: Systematic Review and Meta-Analysis of Randomized, Saline-Controlled Trials
por: Miller, Larry E., et al.
Publicado: (2013)

Spatial Analysis of Global Variability in Covid-19 Burden
por: Miller, Larry E, et al.
Publicado: (2020)

FLT3 tyrosine kinase inhibitors synergize with BCL-2 inhibition to eliminate FLT3/ITD acute leukemia cells through BIM activation
por: Zhu, Ruiqi, et al.
Publicado: (2021)

Red blood cells differentiated in vitro using sequential liquid and semi-solid culture as a pre-clinical model
por: Cannon, Matthew, et al.
Publicado: (2021)

A non-toxic approach for treatment of breast cancer and its metastases: capecitabine enhanced photodynamic therapy in a murine breast tumor model
por: Anand, Sanjay, et al.
Publicado: (2019)

Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study
por: Paz-Ares, Luis, et al.
Publicado: (2023)

Bcl11a Controls Flt3 Expression in Early Hematopoietic Progenitors and Is Required for pDC Development In Vivo
por: Wu, Xiaodi, et al.
Publicado: (2013)

Can You Teach Clinical Communication Virtually?
por: Montgomery, Adam, et al.
Publicado: (2023)

FLT3 inhibition by olverembatinib (HQP1351) downregulates MCL-1 and synergizes with BCL-2 inhibitor lisaftoclax (APG-2575) in preclinical models of FLT3-ITD mutant acute myeloid leukemia
por: Fang, Douglas D., et al.
Publicado: (2021)

Allosteric SHP2 inhibition increases apoptotic dependency on BCL2 and synergizes with venetoclax in FLT3- and KIT-mutant AML
por: Popescu, Bogdan, et al.
Publicado: (2023)

Mutation patterns identify adult patients with de novo acute myeloid leukemia aged 60 years or older who respond favorably to standard chemotherapy: an analysis of Alliance studies
por: Eisfeld, Ann-Kathrin, et al.
Publicado: (2018)

A phase I study of lenalidomide plus chemotherapy with idarubicin and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high‐risk myelodysplastic syndrome
por: Saygin, Caner, et al.
Publicado: (2020)

Framework of clonal mutations concurrent with WT1 mutations in adults with acute myeloid leukemia: Alliance for Clinical Trials in Oncology study
por: Bhatnagar, Bhavana, et al.
Publicado: (2023)

Inhibition of menin, BCL-2, and FLT3 combined with a hypomethylating agent cures NPM1/FLT3-ITD/-TKD mutant acute myeloid leukemia in a patient-derived xenograft model
por: Carter, Bing Z., et al.
Publicado: (2023)

RNA activating-double stranded RNA targeting flt-1 promoter inhibits endothelial cell proliferation through soluble FLT-1 upregulation
por: Choi, Susie, et al.
Publicado: (2018)

Further Activation of FLT3 Mutants by FLT3 Ligand
por: Zheng, Rui, et al.
Publicado: (2011)

NF1 mutations are recurrent in adult acute myeloid leukemia and confer poor outcome
por: Eisfeld, Ann-Kathrin, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_rdhrfnb2vjpogpn4l28gu16sgo